Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Sarah Rasia
Centro Sclerosi Multipla,
P.O. Montichiari, Spedali Civili Brescia, via Ciotti 154, 25018 Montichiari (Bs)
Italy
Research Article
Natalizumab to Fingolimod Switching in Multiple Sclerosis: Results from a “Real Word” Retrospective Analysis
Author(s): Sarah Rasia, Cinzia Cordioli, Nicola De Rossi, Fabiana Pimazzoni, Cristina Scarpazza, Luisa Imberti and Ruggero CapraSarah Rasia, Cinzia Cordioli, Nicola De Rossi, Fabiana Pimazzoni, Cristina Scarpazza, Luisa Imberti and Ruggero Capra
Fingolimod is an alternative for patients with multiple sclerosis who discontinue natalizumab because of leukoencephalopathy risk. However, the interruption of natalizumab might cause disease reactivation. We aimed to describe the disease course of patients switching to fingolimod after treatment with natalizumab or β-interferon, in a real-world setting, through a retrospective analysis of data in patients with multiple sclerosis that receiving fingolimod at a single centre in Italy. Ninety patients were divided into two groups: patients switching to fingolimod from natalizumab (n = 43, Group 1), and treatment naïve (n=5) plus patients switching from β-interferon (n = 42) (Group 2). In Group 1, the mean annualised relapse rate significantly increased from 0.36 at natalizumab discontinuation to 0.80 after natalizumab washout and 1.12 after the first 3 months of fingolimo.. View More»
